What Aptissen does

Aptissen SA is a Swiss musculoskeletal specialist founded in 2013 as a spin-off from Anteis, headquartered in Plan-les-Ouates, Switzerland. The company develops and commercializes orthobiologic solutions for joint disorders, with two core commercial products: Synolis VA, a patented injectable viscosupplement gel combining Hyaluronic Acid and Sorbitol (an antioxidant) available in two concentrations (40mg HA/80mg Sorbitol and 80mg HA/160mg Sorbitol), and Cartylis, a drinkable collagen-based food supplement with vitamins C, D, E, and selenium designed to support joint health. The underlying technology leverages the proprietary HA-Sorbitol combination to create viscoelastic properties similar to healthy young synovial fluid, producing fast pain relief (within one week) with effects lasting up to 6 months based on published clinical evidence.

The company operates a B2B distribution model through five wholly-owned subsidiaries (Italy, Poland, France, Germany, Brazil) and a worldwide distributor network covering more than 50 countries including Switzerland, Canada, Mexico, UAE, Singapore, and Malaysia. Revenue is generated through one-time sales of medical devices to physicians and healthcare providers (primary segment) and consumer-facing nutritional supplements via distributor networks, with pricing not publicly disclosed. Aptissen holds ISO 13485:2016 (2018), CE marking (2019), and MDSAP certification (2020), enabling regulatory access across Europe, Canada, and Brazil. The company's clinical evidence base includes 20+ peer-reviewed publications and quantified outcomes such as 61.8% pain relief and 78.8% OMERACT-OARSI responder rate at 6 months.

Aptissen is actively investing in pipeline expansion (RID-02 for osteoarthritis, TID-03 for tendinopathies, FS02 for osteochondrosis), physician education through Aptissen Academy, and congress-based marketing across major orthopedic and sports medicine events. The company is privately held with 11-50 employees and has completed one disclosed funding round (FONGIT, June 2014).

Name

Aptissen

Legal name

APTISSEN SA

Website

https://aptissen.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Aptissen is a Swiss musculoskeletal specialist that develops and distributes orthobiologic solutions, including the patented Synolis VA injectable viscosupplement and Cartylis collagen supplement, sold to physicians, healthcare providers, and consumers across 50+ countries via direct subsidiaries and distributor networks.

Ownership category

akta.pro rank

Product category

Orthobiologics / Medical Devices for Musculoskeletal Care

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin) (AFAJAKAK)

Keywords

• Orthobiologic solutions
• Viscosupplementation injectables
• Hyaluronic acid treatments
• Joint health supplements
• Osteoarthritis medical devices

Headquarters

HQ city

Plan-les-ouates

HQ country

Switzerland

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others

Revenue model

1. Synolis VA Sales: Sale of patented injectable viscosupplement gel for osteoarthritis treatment. Distributed through direct subsidiaries and worldwide distributor network. Available in two formulations (40/80 and 80/160 HA/Sorbitol).
2. Cartylis Food Supplement Sales: Sale of drinkable food supplement containing collagen, vitamins and selenium for joint health. Sold in packs of 28 vials (25ml each).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Aptissen develops and commercializes orthobiologic solutions for musculoskeletal conditions, primarily Synolis VA, a patented injectable viscosupplement gel combining Hyaluronic Acid and Sorbitol for intra-articular treatment of osteoarthritis. The company also offers Cartylis, a drinkable food supplement containing collagen, vitamins and selenium to support joint health, and maintains a pipeline of medical devices and supplements for osteoarthritis, tendinopathies and osteochondrosis. Products are distributed in 50+ countries via direct subsidiaries and a worldwide distributor network targeting physicians, healthcare providers and pharmaceutical partners.

Product overview

Aptissen is a Swiss musculoskeletal expert founded in 2013 that provides orthobiologic solutions for joint disorders. The company's product portfolio centers on two main commercial offerings: Synolis VA (a viscosupplement injectable gel combining hyaluronic acid and sorbitol, available in two strengths: 40/80 and 80/160 formulations) for intra-articular treatment of osteoarthritis, and Cartylis (a drinkable collagen-based food supplement with vitamins and minerals for daily joint support). Products are distributed through a worldwide network spanning over 50 countries including Switzerland, France, Italy, Poland, Canada, Mexico, Brazil, UAE, Singapore, and Malaysia. The company maintains a development pipeline including medical devices RID-02 (osteoarthritis), TID-03 (tendinopathies), and nutritional supplement FS02 (osteochondrosis).

Differentiator

Problem solved

Functional benefit

Brands

• Synolis VA: Patented injectable viscosupplement gel containing Hyaluronic Acid and Sorbitol for osteoarthritis treatment
• Cartylis
• Healavis

Products and services

• Synolis VA 40mg HA/80mg Sorbitol A patented injectable viscosupplement gel containing 40mg Hyaluronic Acid and 80mg Sorbitol, designed for intra-articular treatment of osteoarthritis. Provides fast pain relief with viscoelastic properties similar to healthy young synovial fluid and effects lasting up to 6 months. Sold to physicians and healthcare providers through distributors and direct subsidiaries.
• Synolis VA 80mg HA/160mg Sorbitol A higher-dose patented injectable viscosupplement gel containing 80mg Hyaluronic Acid and 160mg Sorbitol for intra-articular treatment of osteoarthritis. Offers extended pain relief with the same antioxidant-enhanced viscoelastic properties as the 40/80 formulation, with effects lasting up to 6 months. CE-marked medical device distributed to physicians and healthcare providers.
• Cartylis A drinkable food supplement designed to boost joint health. Contains collagen, vitamin C, vitamin D, vitamin E, and selenium. Each pack contains 28 vials of 25ml with strawberry and banana flavor, intended for daily use over 12 weeks to stimulate joints and promote collagen synthesis. Distributed via the Aptissen distributor and subsidiary network.

Quantifiable outcome

• 61.8% pain relief at 6 months
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Medical and Research InstitutionscoreStrategic or Co-development PartnerAptissen engages in collaborations with universities, foundations, and research institutions for scientific research support. The company emphasizes strategic partnerships in pharmacy, biotechnology, medical techniques, and research to continue providing innovative health solutions.
• Distribution PartnerscoreChannel Partner/ Reseller/ DistributorThe company seeks national and regional distribution partners, as well as licensing partners for products, patents, and technologies. Partners interested in joining the network can apply through regional contact forms.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Zimmer Biomet: Large orthopedic medical device company whose portfolio includes gel-one, an HA viscosupplement. Competes with Aptissen in viscosupplementation as part of a much broader orthopedics and sports medicine portfolio.
• Sanofi: Markets Synvisc and Synvisc-One (hylan G-F 20), historically the leading viscosupplement franchise globally. As a large diversified pharma, Sanofi competes with Synolis VA across all of Aptissen's key markets but does not specialize in the orthobiologic niche.

Direct peers

• Seikagaku Corporation: Japanese specialty company marketing Supartz (sodium hyaluronate) for knee OA in the US and other markets. Direct competitor in viscosupplementation with comparable positioning around purified HA injectables.
• Anika Therapeutics: US-based specialty company commercializing HA viscosupplements (Monovisc, Orthovisc) directly competing with Synolis VA in the intra-articular osteoarthritis treatment category. Closest like-for-like competitor in product profile and indication.
• Bioventus: Markets Durolane and Gelsyn-3, single-injection and multi-injection HA viscosupplements for knee OA, directly competing with Synolis VA. Also active in orthobiologics, an adjacent category to Aptissen's pipeline.
• Fidia Farmaceutici: Italian specialty pharma that developed Hyalgan, one of the original HA viscosupplements for OA. Directly comparable in product (HA injection for joint pain) and regional heritage (European-headquartered, similar LATAM presence).
• IBSA Farmaceutici: Swiss-headquartered specialty pharma marketing Sinovial and other HA-based viscosupplements. Closely comparable in size, Swiss origin, orthobiologic focus, and channel mix targeting physicians for OA treatment.
• Ferring Pharmaceuticals: Sells Euflexxa (1% sodium hyaluronate), a direct viscosupplement competitor to Synolis VA. Privately held Swiss-headquartered pharma with similar European distribution orientation and orthopedics focus.
• LG Chem Life Sciences: Korean life sciences arm of LG Chem that markets Hyruan and other HA viscosupplements in Asia and select global markets. Directly comparable injectable HA product and similar channel approach through local distributors.

Emerging players

• Contipro: Czech manufacturer specializing in hyaluronic acid and other biopolymers for medical, cosmetic, and supplement applications. Operates as a potential supplier/competitor at the upstream end of the HA value chain that Aptissen also serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptissen